Relationship between baseline health-related quality of life (HRQoL) measures and clinical outcomes of nivolumab (NIVO) or nivolumab plus ipilimumab (NIVO plus IPI) in patients (pts) with unresectable or metastatic melanoma using real-world data from the non-interventional study (NIS) NICO in Germany

被引：0

作者：

Gutzmer, R. ^{[1
]}

Ugurel, S. ^{[2
]}

Eigentler, T. ^{[3
]}

Mohr, P. ^{[4
]}

Weichenthal, M. ^{[5
]}

Gebhardt, C. ^{[6
]}

Goeppner, D. ^{[7
]}

Haferkamp, S. ^{[8
]}

Herbst, R. ^{[9
]}

Kaehler, K. C. ^{[5
]}

Kreuter, A. ^{[10
]}

Meier, F. ^{[11
]}

Pfoehler, C. ^{[12
]}

Sachse, M. M. ^{[13
]}

Herber, M. ^{[14
]}

Terheyden, P. ^{[15
]}

Ulrich, J. ^{[16
]}

Utikal, J. S. ^{[17
]}

von Wasielewski, I. ^{[18
]}

Schadendorf, D. ^{[2
]}

机构：

[1] Ruhr Univ Bochum, Univ Klinikum, Minden, Germany

[2] Univ Klinikum Essen, Essen, Germany

[3] Charite Univ Med Berlin, Berlin, Germany

[4] Elbe Kliniken Buxtehude, Buxtehude, Germany

[5] Univ Klinikum Schleswig Holstein, Kiel, Germany

[6] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany

[7] Justus Liebig Univ Giessen, Giessen, Germany

[8] Univ Klinikum Regensburg, Regensburg, Germany

[9] Helios Klinikum Erfurt, Erfurt, Germany

[10] Helios St Elisabeth Klin Oberhausen, Oberhausen, Germany

[11] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Dresden & Klin Dermatol, Hauttumorzentrum NCT UCC, Dresden, Germany

[12] Univ Klinikum Saarlandes, Homburg, Germany

[13] Klinikum Bremerhaven, Bremerhaven, Germany

[14] Bristol Myers Squibb, Munich, Germany

[15] Univ Klinikum Schleswig Holstein, Lubeck, Germany

[16] Harzklinikum Dorothea Christiane Erxleben, Quedlinburg, Germany

[17] Ruprecht Karl Univ Heidelberg, Univ Klinikum Mannheim, Mannheim, Germany

[18] Hannover Med Sch, Haut Tumor Zentrum, Hannover, Germany

来源：

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

FV07

引用

页码：6 / 8

页数：3

共 18 条

[1] Real World Data on the Use of Nivolumab (Nivo) as Monotherapy or in Combination with Ipilimumab (Nivo plus Ipi) in the Treatment of advanced Melanoma: Interim Results of the non-interventional Study NICO
Ugurel, S.
Satzger, I.
Eigentler, T.
Mohr, P.
Goeppner, D.
Herber, M.
Herbst, R.
Kaehler, K. C.
Meier, F.
Meiss, F.
Pfoehler, C.
Sachse, M. M.
Schneider, S. W.
Terheyden, P.
Ulrich, J.
Utikal, J. S.
Welzel, J.
Schadendorf, D.
Gutzmer, R.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 69 - 70
[2] Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO plus IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO
Gutzmer, R.
Eigentler, T.
Mohr, P.
Weichenthal, M.
Duecker, P.
Gebhardt, C.
Goeppner, D.
Haferkamp, S.
Kaehler, K.
Meier, F.
Pfoehler, C.
Satzger, I.
Sickmann, T.
Sindrilaru, A.
Terheyden, P.
Ugurel, S.
Ulrich, J.
Utikal, J.
Weishaupt, C.
Schadendorf, D.
ANNALS OF ONCOLOGY, 2020, 31 : S746 - S747
[3] Age-dependent Efficacy and Safety of Nivolumab (NIVO) as Monotherapy or Combination Therapy with Ipilimumab (NIVO plus IPI) in Patients with advanced Melanoma in the non-interventional Study (NIS) NICO
Schadendorf, D.
Ugurel, S.
Eigentler, T.
Mohr, P.
Wei-Chenthal, M.
Gebhardt, C.
Goppner, D.
Haferkamp, S.
Herbst, R.
Kahler, K.
Kreuter, A.
Meier, F.
Pfohler, C.
Sachse, M. M.
Sickmann, T.
Terheyden, P.
Ulrich, J.
Utikal, J. S.
Grimmel-Mann, I.
Gutzmer, R.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 16 - 17
[4] Use of nivolumab (NIVO) in adjuvant melanoma patients: real world data from NICO, a national prospective non-interventional study
Gutzmer, Ralf
Mohr, Peter
Eigentler, Thomas
Grimmelmann, Imke
Zimmer, Lisa
Livingstone, Elisabeth
Ugurel, Selma
Utikal, Jochen
Mueller, Verena
Goeppner, Daniela
Herbst, Rudolf
Kreuter, Alexander
Pfoehler, Claudia
Hollburg, Wiebke
Carmen, Loquai
Herber, Martin
Kaehler, Katharina C.
Weichenthal, Michael
Schadendorf, Dirk
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 236 - 237
[5] NICO - a national prospective non-interventional Study (NIS) with Nivolumab as Monotherapy or in combination with Ipilimumab in Patients with advanced (inoperable or metastatic) Melanoma to collect real-world data
Gutzmer, R.
Eigentler, T.
Mohr, P.
Becker, S.
Haferkamp, S.
Meiss, F.
Pfoehler, C.
Satzger, I.
Schneider, S. W.
Terheyden, P.
Ulrich, J.
Utikal, J.
Weichenthal, M.
Weishaupt, C.
Zimmer, L.
Schadendorf, D.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 79 - 79
[6] Real-world evidence in melanoma: A national, prospective, non-interventional study (NIS) of nivolumab monotherapy or in combination with ipilimumab in patients with advanced (unresected or metastatic) melanoma (NICO)
Eigentler, T.
Gutzmer, R.
Mohr, P.
Kaatz, M.
Pfohler, C.
Terheyden, P.
Ulrich, J.
Utikal, J.
Zimmer, L.
Schadendorf, D.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 159 - 159
[7] Interim data of effectiveness and safety of nivolumab plus ipilimumab combination therapy (NIVO plus IPI) in first line (1L) advanced/metastatic renal cell carcinoma (aRCC) from the German non-interventional study (NIS) NORA
Bedke, Jens
Mueller-Huesmann, Harald
Belz, Hanjo
von der Heyde, Eyck
Boegemann, Martin
Strauss, Arne
Ivanyi, Philipp
Wiegand, Jörg
Autengruber, Andrea
Grimm, Marc-Oliver
Gruenwald, Viktor
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 103 - 104
[8] Health-related quality of life (HRQoL) in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC) treated with nivolumab (N) plus chemotherapy (CT) or nivo plus ipilimumab (I) versus chemo: Results from CheckMate 648
Bridgewater, John A.
Chau, Ian
Gricar, Joseph
Blum, Steven I.
Taylor, Fiona
Lawrance, Rachael
Padilla, Brad
Yip, Christine
Wyrwicz, Lucjan
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[9] First-line nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC): Results from an interim analysis of the non-interventional FINN study
Kuon, J. B.
von der Heyde, E.
Wilop, S.
Behringer, D. M.
Blau, W.
Huebner, G.
Flieger, D.
Forstbauer, H.
Groschek, M.
Laack, H-E.
Mueller-Huesmann, H.
Schumann, C.
Waldenberger, D.
Guetz, S.
ANNALS OF ONCOLOGY, 2023, 34
[10] HANNA: Effectiveness and quality-of-life data from a real-world study of patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab (NIVO) in Germany
Mueller-Huesmann, Harald
von der Heyde, Eyck
Hahn, Dennis
Langer, Christine
Kubuschok, Boris
Bockmuehl, Ulrike
Klautke, Gunter
Mauz, Paul-Stefan
Reuter, Bernd
Beutner, Dirk
Buentzel, Jens
von der Gruen, Jens
Busch, Chia-Jung
Tamaskovics, Balint
Riera-Knorrenschild, Jorge
Gutsche, Kerstin
Welslau, Manfred
Gauler, Thomas
Waldenberger, Daniela
Dietz, Andreas
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 125 - 125

← 1 2 →